COVI-VAC (U.S. COVID-19 vaccine)
This is an old revision of this page, as edited by 82.169.161.105 (talk) at 22:19, 2 November 2021 (→Medical uses: Removed the words: in two weeks the vaccine is administered intranasally and requires a single dose ( in two weeks).). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | CDX-005[1] |
| Other names | Covi-Vax |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine being developed by Codagenix, Inc. It is currently in Phase I clinical trials, involving 48 participants which runs from December 2020 to June 2021.[2][3]
Medical uses
the vaccine is administered intranasally and requires a single dose.[2]
Pharmachology
COVI-VAC is a live attenuated vaccine.[4]
Clinical trials
Phase I
In December 2020, Codagenix started fo the phase I trial in the United Kingdom.[2]
In September 2021, Codagenix reported the Phase I trial had shown safety and immunogenicity results.[5]
References
- ^ "Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine". mint. 22 September 2020.
- ^ a b c "Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. Retrieved 8 June 2021.
- ^ Wang Y, Yang C, Song Y, Coleman JR, Stawowczyk M, Tafrova J, et al. (July 2021). "Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy". Proceedings of the National Academy of Sciences of the United States of America. 118 (29): e2102775118. doi:10.1073/pnas.2102775118. PMC 8307828. PMID 34193524.
- ^ "COVI-VAC for SARS-CoV-2 (COVID-19)". Codagenix, Inc. Retrieved 8 June 2021.
- ^ Inc, Codagenix. "Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies". www.prnewswire.com. Retrieved 23 September 2021.
{{cite web}}:|last=has generic name (help)
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
 | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- CS1 errors: generic name
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from June 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles